Dabur Pharma introduces Nanoxel in India

3494 Investors following Fresenius Kabi. Share this News with them.

0

Like this story, share it with millions of investors on M3

Dabur Pharma introduces Nanoxel in India

Dabur Pharma introduces Nanoxel in India

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Dabur Pharma make smart gains Dabur Pharma arrested decline in profits: Anand Rathi Have filed four ANDAs: Dabur Pharma Dabur Pharma Q2 net profit at Rs 6.96cr ALSO READ See latest News about Fresenius Kabi See previous management interviews See what other Experts & Brokerages are saying about Fresenius Kabi Fresenius Kabi BSE | NSE 30/05/12 Are Mutual Funds betting on Fresenius Kabi?

"The introduction of Nanoxel in India reinforces Dabur Pharma's image as a significant company with an in-house capability to develop critical anti-cancer products as well as proprietary technologies that considerably accelerate the ongoing research and development work at its research facility. We also plan to rollout the novel chemotherapy drug delivery formulation internationally in the near future", said Mr. Ajay K Vij, COO, Dabur Pharma Ltd.

Cancer as one of the principal chronic non-communicable diseases is a prime public health concern and affects approximately 1 million new cases every year in India. As most anticancer drugs are designed to simply kill cancer cells, often in a randomly defined manner, the distribution of anticancer drugs in healthy organs or tissues is especially undesirable due to the potential for severe side effects. Consequently the threat of side effects greatly limits the maximum allowable dosage of the drug.

"The biggest challenge that we face in cancer therapy is the incidence of severe side effects that the cancer patient has to encounter while undergoing chemotherapy. Nanoparticle drug delivery devices like Nanoxel enable therapy to take a preferential course to the cancerous cells and directly interact with the tumor causing agents thereby throwing open a larger window for anti-tumor activity. It also ensures that the patient receives the full measure of the therapy while limiting the adverse side effects and toxicity affected by the drug", said Dr. SH Advani, Director of Medical Oncology, Jaslok Hospital & Research Center.

Nanoxel is available to all specialist cancer therapy providers and healthcare institutes for cancer treatment from January 4, 2007. The price of this nanoparticle drug delivery system for paclitaxel has been pegged at INR

16,000 for one cycle of chemotherapy administration. 

Sourced From :Imprimis Life PR